Latest Pro Medicus (ASX:PME) News

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.30 per share for the fiscal year ending June 30, 2025, signaling steady returns for shareholders.

Pro Medicus Limited has delivered a record-breaking FY2025 with soaring profits and a wave of major US healthcare contracts, setting the stage for continued expansion.

Pro Medicus Limited has reported a robust FY25 with revenue climbing nearly 32% and net profit up 39%, prompting a significant dividend increase.

Pro Medicus Limited has entered a strategic financing arrangement with 4DMedical to accelerate the development and commercialization of cutting-edge lung function imaging software.

Pro Medicus has secured a landmark 10-year, A$170 million contract to deploy its cloud-based Visage 7 imaging platform across UCHealth’s extensive hospital network in the US Rocky Mountain region.

Pro Medicus Limited has renewed a significant five-year contract with Franciscan Missionaries of Our Lady Health System, marking a strategic shift to cloud-based medical imaging solutions and promising new revenue streams.

Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, has landed a significant five-year, A$20 million contract to implement its cloud-based Visage 7 imaging platform at University of Iowa Health Care, marking a major step in cloud adoption for healthcare IT.

Pro Medicus has delivered a record first half in FY25, driven by strong revenue growth, major contract wins, and successful implementations that position it well for future expansion.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.25 per share for the six months ending December 2024, signaling continued shareholder returns without the need for external approvals.

Pro Medicus Limited has delivered a record interim profit of $51.7 million, boosted by major North American contract wins and strong margin expansion.

Pro Medicus Limited delivered a robust half-year performance ending December 2024, with after-tax profits soaring 42.7% to $51.74 million and revenues climbing 31.1% to $97.2 million, driven by significant contract wins in North America and sustained growth in Australia.

Pro Medicus Limited has reported a robust half-year financial performance for the period ending December 31, 2024, with net profit soaring 42.7% and an increased interim dividend declared.